Misra Gauri, Wegerif Simon, Fairlie Louise, Kapoor Melissa, Fok James, Salt Gemma, Halbert Jay, Maconochie Ian, Mullen Niall
Mind over Matter Medtech Ltd, London, United Kingdom.
Xim Limited, Southampton, United Kingdom.
JMIR Res Protoc. 2025 Mar 14;14:e58334. doi: 10.2196/58334.
Measuring vital signs (VS) is important in potentially unwell children, as a change in VS may indicate a more serious infection than is clinically apparent or herald clinical deterioration. However, currently available methods are not suitable for regular measurement of VS in the home or community setting, and adherence can be poor. The COVID-19 pandemic highlighted a need for the contactless measurement of VS by nonclinical personnel, reinforced by the growing use of telemedicine. The Lifelight app is being developed as a medical device for the contactless measurement of VS using remote photoplethysmography via the camera on smart devices. The VISION-D (Measurement of Vital Signs by Lifelight Software in Comparison to the Standard of Care-Development) and -V (Validation) studies demonstrated the accuracy of the app compared with standard of care (SOC) measurement of blood pressure, pulse rate (PR), and respiratory rate (RR) in adults, supporting certification of Lifelight as a class I Conformité Européenne medical device.
To support the development of the Lifelight app for pediatric patients, the VISION-Junior study is collecting high-quality data that will be used to develop algorithms for the measurement of VS (PR, RR, and oxygen saturation) in pediatric patients. The accuracy of the app will be assessed against SOC measurements made simultaneously with app measurements.
The study is recruiting pediatric patients (younger than 18 years of age) attending the Sunderland Royal Hospital pediatric emergency department of the South Tyneside and Sunderland National Health Service Foundation Trust. High-resolution videos of the face (and torso in children younger than 5 years of age) and audio recordings (to explore the value of crying, wheezing, coughing, and other sounds in predicting illness) are made using the Lifelight Data Collect app. VS are measured simultaneously using SOC methods (finger clip sensor for PR and oxygen saturation; manual counting of RR). Feedback from patients, parents, carers, and nurses who use Lifelight is collected via questionnaires. Anticipated recruitment is 500 participants, with subtargets for age, sex, and skin tone distribution (Fitzpatrick 6-point scale). Early data will be used to refine the algorithms. A separate dataset will be retained to test the performance of the app against predefined targets.
The study started on June 12, 2023, and reached its recruitment target (n=532) in April 2024 after extending the deadline. Algorithm refinement is in progress, after which the performance of Lifelight will be compared with the SOC measurement of VS. The analyses are expected to be completed by mid-August 2024.
Data collected in this study will be used to develop and assess the accuracy of the app for the measurement of VS in pediatric patients of all ages.
ClinicalTrials.gov NCT05850013; https://clinicaltrials.gov/study/NCT05850013.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/58334.
测量生命体征(VS)对可能身体不适的儿童很重要,因为生命体征的变化可能表明存在比临床明显症状更严重的感染,或预示着临床病情恶化。然而,目前可用的方法不适合在家中或社区环境中定期测量生命体征,且依从性可能较差。新冠疫情凸显了非临床人员进行非接触式生命体征测量的必要性,远程医疗的日益普及进一步强化了这一需求。Lifelight应用程序正在开发成为一种医疗设备,可通过智能设备上的摄像头利用远程光电容积脉搏波描记法进行非接触式生命体征测量。VISION-D(Lifelight软件测量生命体征与护理标准对比 - 开发)和-V(验证)研究证明了该应用程序与成人护理标准(SOC)测量血压、脉搏率(PR)和呼吸率(RR)相比的准确性,支持Lifelight作为I类欧洲符合性医疗设备的认证。
为支持Lifelight应用程序在儿科患者中的开发,VISION-Junior研究正在收集高质量数据,这些数据将用于开发测量儿科患者生命体征(脉搏率、呼吸率和血氧饱和度)的算法。将根据与应用程序测量同时进行的护理标准测量来评估该应用程序的准确性。
该研究正在招募泰恩赛德南部和桑德兰国民保健服务基金会信托基金桑德兰皇家医院儿科急诊科的儿科患者(年龄小于18岁)。使用Lifelight数据收集应用程序拍摄面部(5岁以下儿童还包括躯干)的高分辨率视频以及音频记录(以探索哭泣、喘息、咳嗽和其他声音在预测疾病方面的价值)。同时使用护理标准方法测量生命体征(用手指夹式传感器测量脉搏率和血氧饱和度;手动计数呼吸率)。通过问卷收集使用Lifelight的患者、父母、护理人员和护士的反馈。预计招募人数为500名参与者,并针对年龄、性别和肤色分布(菲茨帕特里克6分制)设定子目标。早期数据将用于优化算法。将保留一个单独的数据集以根据预定义目标测试该应用程序的性能。
该研究于2023年6月12日开始,在延长截止日期后于2024年4月达到招募目标(n = 532)。算法优化正在进行中,之后将把Lifelight的性能与生命体征的护理标准测量进行比较。分析预计于2024年8月中旬完成。
本研究收集的数据将用于开发和评估该应用程序在各年龄段儿科患者中测量生命体征的准确性。
ClinicalTrials.gov NCT05850013;https://clinicaltrials.gov/study/NCT05850013。
国际注册报告标识符(IRRID):DERR1-10.2196/58334。